Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms
暂无分享,去创建一个
F. Goldwasser | V. Girre | V. Diéras | V. Jullien | J. Treluyer | G. Pons | J. Alexandre | E. Rey | A. Tran | F. Rabillon | V. Jullien | V. Diéras | J. Tréluyer | V. Jullien
[1] J. Verweij,et al. Clinical Pharmacokinetics of Docetaxel , 2006, Clinical pharmacokinetics.
[2] M. Haberl,et al. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations , 2006, Pharmacogenetics and genomics.
[3] Lewis B. Sheiner,et al. A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[4] D. Greenblatt,et al. Genotype‐phenotype Associations of Cytochrome P450 3A4 and 3A5 Polymorphism with Midazolam Clearance in Vivo , 2005, Clinical pharmacology and therapeutics.
[5] G. Hortobagyi,et al. Docetaxel for treatment of solid tumours: a systematic review of clinical data. , 2005, The Lancet. Oncology.
[6] P. Beaune,et al. Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] Shinzaburo Noguchi,et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Verweij,et al. Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia , 2005, Clinical pharmacology and therapeutics.
[9] T. Rebbeck,et al. CYP3A4, CYP3A5, and CYP3A43 Genotypes and Haplotypes in the Etiology and Severity of Prostate Cancer , 2004, Cancer Research.
[10] Yingjin Yuan,et al. Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. , 2004, Cancer letters.
[11] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[12] C. Verlinde,et al. Characterization of atrazine biotransformation by human and murine glutathione S-transferases. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[13] F. Dalenc,et al. Dexamethasone as a probe for docetaxel clearance , 2004, Cancer Chemotherapy and Pharmacology.
[14] C. Flamant,et al. Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis. , 2004, Pharmacogenetics.
[15] A. Telenti,et al. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects , 2004, European Journal of Clinical Pharmacology.
[16] T. Rebbeck,et al. CYP 3 A 4 , CYP 3 A 5 , and CYP 3 A 43 Genotypes and Haplotypes in the Etiology and Severity of Prostate Cancer , 2004 .
[17] H. Dienemann,et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. , 2003, Pharmacogenetics.
[18] W. Weimar,et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.
[19] Ji-yao Wang,et al. Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis. , 2003, World journal of gastroenterology.
[20] M. Spitz,et al. Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. , 2003, Lung cancer.
[21] T. Rebbeck,et al. Increased transcriptional activity of the CYP3A4*1B promoter variant , 2003, Environmental and molecular mutagenesis.
[22] F. Ali-Osman,et al. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. , 2002, Pharmacogenetics.
[23] B. Goh,et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Giles,et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. , 2002, Pharmacogenetics.
[25] K. Tanimoto,et al. Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. , 2002, International Journal of Oncology.
[26] Jacques Fellay,et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.
[27] L. Hutchins,et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. , 2001, Cancer research.
[28] M. Fromm,et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. , 2001, Pharmacogenetics.
[29] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[30] C. Meisel,et al. Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.
[31] C. Veyrat‐Follet,et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization , 2000, Clinical pharmacology and therapeutics.
[32] S. Ackland,et al. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. , 2000, Journal of chromatography. B, Biomedical sciences and applications.
[33] J. Hayes,et al. Glutathione S-Transferase Polymorphisms and Their Biological Consequences , 2000, Pharmacology.
[34] S. Clark,et al. A Distinct Sequence (ATAAA) n Separates Methylated and Unmethylated Domains at the 5′-End of theGSTP1 CpG Island*210 , 2000, The Journal of Biological Chemistry.
[35] J. Verweij,et al. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] N. Saijo,et al. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] P. Watkins,et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] J. Verweij,et al. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] U. Brinkmann,et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[40] D. Bowen,et al. Glutathione S-transferase enzyme expression in hematopoietic cell lines implies a differential protective role for T1 and A1 isoenzymes in erythroid and for M1 in lymphoid lineages. , 2000, Haematologica.
[41] P. Hopkins,et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4 , 1999, Clinical pharmacology and therapeutics.
[42] L. Rivory,et al. Clinical Pharmacokinetics of Docetaxel , 1999, Clinical pharmacokinetics.
[43] K. Korzekwa,et al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. , 1998, Pharmacogenetics.
[44] G. B. Smith,et al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. , 1998, Carcinogenesis.
[45] L B Sheiner,et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] J. Verweij,et al. Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] D. Forman,et al. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. , 1997, Carcinogenesis.
[48] J. Buolamwini,et al. Molecular Cloning, Characterization, and Expression in Escherichia coli of Full-length cDNAs of Three Human Glutathione S -Transferase Pi Gene Variants EVIDENCE FOR DIFFERENTIAL CATALYTIC ACTIVITY OF THE ENCODED PROTEINS* , 1997 .
[49] J. Beijnen,et al. Isolation, purification and biological activity of major docetaxel metabolites from human feces. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[50] I. Roninson,et al. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.
[51] T. Triche,et al. An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue. , 1990, The American journal of pathology.
[52] A Schumitzky,et al. A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.